These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 25394031)

  • 1. A community perspective on pre-exposure prophylaxis.
    Collins S
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19522. PubMed ID: 25394031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acceptability of an "on-demand" pre-exposure HIV prophylaxis trial among men who have sex with men living in France.
    Lorente N; Fugon L; Carrieri MP; Andreo C; Le Gall JM; Cook E; Aboulker JP; Capitant C; Molina JM; Spire B
    AIDS Care; 2012; 24(4):468-77. PubMed ID: 22085083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of pre-exposure prophylaxis for HIV: a review.
    Schackman BR; Eggman AA
    Curr Opin HIV AIDS; 2012 Nov; 7(6):587-92. PubMed ID: 23076124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of antiretroviral therapy for the prevention of new HIV infection in populations at high risk for HIV sero-conversion in Nigeria.
    Idoko J; Folayan MO
    Afr J Reprod Health; 2014 Sep; 18(3 Spec No):127-34. PubMed ID: 26050385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Willingness to use HIV pre-exposure prophylaxis and the likelihood of decreased condom use are both associated with unprotected anal intercourse and the perceived likelihood of becoming HIV positive among Australian gay and bisexual men.
    Holt M; Murphy DA; Callander D; Ellard J; Rosengarten M; Kippax SC; de Wit JB
    Sex Transm Infect; 2012 Jun; 88(4):258-63. PubMed ID: 22290327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Where to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa?
    Verguet S; Stalcup M; Walsh JA
    Sex Transm Infect; 2013 Dec; 89(8):628-34. PubMed ID: 23912819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review.
    Hankins CA; Dybul MR
    Curr Opin HIV AIDS; 2013 Jan; 8(1):50-8. PubMed ID: 23201856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microbicides-emerging essential pillars of comprehensive HIV/AIDS prevention.
    Gaym A
    Ethiop Med J; 2006 Oct; 44(4):405-15. PubMed ID: 17370443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Untangling the cost-effectiveness knot: who is oral antiretroviral HIV pre-exposure prophylaxis really for?
    Hankins CA
    Expert Rev Pharmacoecon Outcomes Res; 2014 Apr; 14(2):167-70. PubMed ID: 24552641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preexposure prophylaxis for the prevention of HIV transmission to women.
    Aaron E; Cohan D
    AIDS; 2013 Jan; 27(1):F1-5. PubMed ID: 22914582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Animal models of antiretroviral prophylaxis for HIV prevention.
    García-Lerma JG; Heneine W
    Curr Opin HIV AIDS; 2012 Nov; 7(6):505-13. PubMed ID: 22964889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attitudes of serodiscordant couples towards antiretroviral-based HIV prevention strategies in Kenya: a qualitative study.
    Fowler N; Arkell P; Abouyannis M; James C; Roberts L
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19563. PubMed ID: 25394070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The key role of adherence for the effectiveness of antiretroviral-based prevention: state of the science and implications for the Asia-Pacific region.
    Amico KR
    Sex Health; 2014 Jul; 11(2):155-65. PubMed ID: 24331438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attitudes towards new HIV biomedical prevention technologies among a cohort of HIV-negative gay men in Sydney, Australia.
    Poynten IM; Jin F; Prestage GP; Kaldor JM; Imrie J; Grulich AE
    HIV Med; 2010 Apr; 11(4):282-8. PubMed ID: 20015220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refocusing the debate: evidence-based clinical cancer research versus marketplace reality.
    Markman M
    J Oncol Pract; 2008 Sep; 4(5):231. PubMed ID: 20856701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Barriers to uptake and use of pre-exposure prophylaxis (PrEP) among communities most affected by HIV in the UK: findings from a qualitative study in Scotland.
    Young I; Flowers P; McDaid LM
    BMJ Open; 2014 Nov; 4(11):e005717. PubMed ID: 25412863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two years of Truvada for pre-exposure prophylaxis utilization in the US.
    Flash C; Landovitz R; Giler RM; Ng L; Magnuson D; Wooley SB; Rawlings K
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19730. PubMed ID: 25397476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretrovirals for primary HIV prevention: the current status of pre- and post-exposure prophylaxis.
    Krakower DS; Jain S; Mayer KH
    Curr HIV/AIDS Rep; 2015 Mar; 12(1):127-38. PubMed ID: 25600106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medication adherence among men who have sex with men at risk for HIV infection in the United States: implications for pre-exposure prophylaxis implementation.
    Liu AY; Hessol NA; Vittinghoff E; Amico KR; Kroboth E; Fuchs J; Irvin R; Sineath RC; Sanchez T; Sullivan PS; Buchbinder SP
    AIDS Patient Care STDS; 2014 Dec; 28(12):622-7. PubMed ID: 25396706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
    Krakower DS; Mayer KH
    Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.